Try free for 30 days
-
Drugs and the FDA
- Safety, Efficacy, and the Public's Trust
- Narrated by: Mike Lenz
- Length: 8 hrs and 40 mins
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Buy Now for $26.99
No valid payment method on file.
We are sorry. We are not allowed to sell this product with the selected payment method
Listeners also picked
-
Living Medicine
- Don Thomas, Marrow Transplantation, and the Cell Therapy Revolution
- By: Dr. Fred Appelbaum
- Narrated by: Nathan Agin
- Length: 11 hrs and 50 mins
- Unabridged
-
Overall
-
Performance
-
Story
In the last half of the twentieth century, Don Thomas discovered a cure for every marrow-based disease—like leukemia, lymphoma, and sickle-cell anemia—forever changing treatment for some of the deadliest illnesses. His feats were extraordinary, earning him a Nobel Prize, and the cascade of treatments he inspired have reshaped and will continue to reshape the practice of clinical medicine. Yet no one has ever written Thomas’s courageous story.Dr. Frederick R. Appelbaum, a member of Thomas’s research team, does so for the first time.
-
The AI Revolution in Medicine
- GPT-4 and Beyond
- By: Peter Lee, Carey Goldberg, Isaac Kohane
- Narrated by: J. Hunter Ackerman
- Length: 7 hrs and 24 mins
- Unabridged
-
Overall
-
Performance
-
Story
Just months ago, millions of people were stunned by ChatGPT's amazing abilities–and its bizarre hallucinations. But that was 2022. GPT-4 is now here, with smarter, more accurate, and deeper technical knowledge. GPT-4 and its competitors and followers are on the verge of transforming medicine. But with lives on the line, you need to understand these technologies–stat.
-
Genentech
- The Beginnings of Biotech
- By: Sally Smith Hughes
- Narrated by: Suzie Althens
- Length: 7 hrs and 12 mins
- Unabridged
-
Overall
-
Performance
-
Story
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.
-
-
Great piece of history
- By Ryan G. on 27-02-2023
-
The Messenger
- Moderna, the Vaccine, and the Business Gamble That Changed the World
- By: Peter Loftus
- Narrated by: Mike Lenz
- Length: 10 hrs and 30 mins
- Unabridged
-
Overall
-
Performance
-
Story
At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of a potentially breakthrough innovation: using RNA to combat disease. Investors were getting antsy or, worse, skeptical. Then the coronavirus pandemic hit, and Moderna became a central player. Wall Street Journal reporter Peter Loftus brings the inside story of how Moderna went all in on a single revolutionary idea.
-
-
You got the vaccine, now read the book
- By Anonymous User on 17-10-2022
-
The Billion Dollar Molecule
- One Company's Quest for the Perfect Drug
- By: Barry Werth
- Narrated by: Stephen Bowlby
- Length: 18 hrs and 25 mins
- Unabridged
-
Overall
-
Performance
-
Story
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.
-
When Blood Breaks Down
- Life Lessons from Leukemia
- By: Mikkael A. Sekeres
- Narrated by: Mike Lenz
- Length: 7 hrs and 28 mins
- Unabridged
-
Overall
-
Performance
-
Story
When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the awful puzzle of bone marrow gone wrong. The two of you are in it together. In When Blood Breaks Down, Mikkael Sekeres, a leading cancer specialist, takes listeners on the journey that patient and doctor travel together.
-
Living Medicine
- Don Thomas, Marrow Transplantation, and the Cell Therapy Revolution
- By: Dr. Fred Appelbaum
- Narrated by: Nathan Agin
- Length: 11 hrs and 50 mins
- Unabridged
-
Overall
-
Performance
-
Story
In the last half of the twentieth century, Don Thomas discovered a cure for every marrow-based disease—like leukemia, lymphoma, and sickle-cell anemia—forever changing treatment for some of the deadliest illnesses. His feats were extraordinary, earning him a Nobel Prize, and the cascade of treatments he inspired have reshaped and will continue to reshape the practice of clinical medicine. Yet no one has ever written Thomas’s courageous story.Dr. Frederick R. Appelbaum, a member of Thomas’s research team, does so for the first time.
-
The AI Revolution in Medicine
- GPT-4 and Beyond
- By: Peter Lee, Carey Goldberg, Isaac Kohane
- Narrated by: J. Hunter Ackerman
- Length: 7 hrs and 24 mins
- Unabridged
-
Overall
-
Performance
-
Story
Just months ago, millions of people were stunned by ChatGPT's amazing abilities–and its bizarre hallucinations. But that was 2022. GPT-4 is now here, with smarter, more accurate, and deeper technical knowledge. GPT-4 and its competitors and followers are on the verge of transforming medicine. But with lives on the line, you need to understand these technologies–stat.
-
Genentech
- The Beginnings of Biotech
- By: Sally Smith Hughes
- Narrated by: Suzie Althens
- Length: 7 hrs and 12 mins
- Unabridged
-
Overall
-
Performance
-
Story
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading. Coming at a time of economic recession and declining technological competitiveness in the United States, the event ignited a period of speculative frenzy over biotechnology.
-
-
Great piece of history
- By Ryan G. on 27-02-2023
-
The Messenger
- Moderna, the Vaccine, and the Business Gamble That Changed the World
- By: Peter Loftus
- Narrated by: Mike Lenz
- Length: 10 hrs and 30 mins
- Unabridged
-
Overall
-
Performance
-
Story
At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of a potentially breakthrough innovation: using RNA to combat disease. Investors were getting antsy or, worse, skeptical. Then the coronavirus pandemic hit, and Moderna became a central player. Wall Street Journal reporter Peter Loftus brings the inside story of how Moderna went all in on a single revolutionary idea.
-
-
You got the vaccine, now read the book
- By Anonymous User on 17-10-2022
-
The Billion Dollar Molecule
- One Company's Quest for the Perfect Drug
- By: Barry Werth
- Narrated by: Stephen Bowlby
- Length: 18 hrs and 25 mins
- Unabridged
-
Overall
-
Performance
-
Story
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.
-
When Blood Breaks Down
- Life Lessons from Leukemia
- By: Mikkael A. Sekeres
- Narrated by: Mike Lenz
- Length: 7 hrs and 28 mins
- Unabridged
-
Overall
-
Performance
-
Story
When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the awful puzzle of bone marrow gone wrong. The two of you are in it together. In When Blood Breaks Down, Mikkael Sekeres, a leading cancer specialist, takes listeners on the journey that patient and doctor travel together.
Publisher's Summary
Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate United States authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former chair of the FDA's cancer drug advisory committee—tells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices.
Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But then, throughout the twentieth century, the government was forced to take action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member.